Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Background: Despite advances in treatment, acute variceal haemorrhage remains life-threatening. Aim: To describe contemporary characteristics, management and outcomes of patients with cirrhosis and acute variceal haemorrhage and risk factors for rebleeding and mortality. Methods: Multi-centre clinical audit conducted in 212 UK hospitals. Results: In 526 cases of acute variceal haemorrhage, 66% underwent endoscopy within 24. h with 64% (n= 339) receiving endoscopic therapy. Prior to endoscopy, 57% (n= 299) received proton pump inhibitors, 44% (n= 232) vasopressors and 27% (n= 144) antibiotics. 73% (n= 386) received red cell transfusion, 35% (n= 184) fresh frozen plasma and 14% (n= 76) platelets, with widely varying transfusion thresholds. 26% (n= 135) experienced further bleeding and 15% (n= 80) died by day 30. The Model for End Stage Liver Disease score was the best predictor of mortality (area under the receiver operating curve. = 0.74, P< 0.001). Neither the clinical nor full Rockall scores were useful predictors of outcome. Coagulopathy was strongly associated with rebleeding (odds ratio 2.23, 95% CI 1.22-4.07, P= 0.01, up to day 30) and mortality (odds ratio 3.06, 95% CI 1.29-7.26, P= 0.01). Conclusions: Although mortality has improved following acute variceal haemorrhage, rebleeding rates remain appreciably high. There are notable deficiencies in the use of vasopressors and endoscopic therapy. More work is needed to understand the optimum transfusion strategies. Better risk stratification tools are required to identify patients needing more intensive support. © 2013 Editrice Gastroenterologica Italiana S.r.l.

Original publication




Journal article


Digestive and Liver Disease

Publication Date





419 - 426